Aneurysmal subarachnoid hemorrhage (aSAH) is a devastating cerebrovascular event with long-term morbidity and mortality. Patients who survive the initial bleeding are likely to suffer further early brain injury arising from a plethora of pathological processes. These may result in a worsening of outcome or death in approximately 25% of patients and may contribute to longer-term cognitive dysfunction in survivors. Inflammation, mediated by the cytokine interleukin-1 (IL-1), is an important contributor to cerebral ischemia after diverse forms of brain injury, including aSAH. Its effects are attenuated by its naturally occurring antagonist, IL-1 receptor antagonist (IL-1Ra [anakinra]). The authors hypothesized that administration of additional subcutaneous IL-1Ra would reduce inflammation and associated plasma markers associated with poor outcome following aSAH.
This was a randomized, open-label, single-blinded study of 100 mg subcutaneous IL-1Ra, administered twice daily in patients with aSAH, starting within 3 days of ictus and continuing until 21 days postictus or discharge from the neurosurgical center, whichever was earlier. Blood samples were taken at admission (baseline) and at Days 3–8, 14, and 21 postictus for measurement of inflammatory markers. The primary outcome was difference in plasma IL-6 measured as area under the curve between Days 3 and 8, corrected for baseline value. Secondary outcome measures included similar area under the curve analyses for other inflammatory markers, plasma pharmacokinetics for IL-1Ra, and clinical outcome at 6 months.
Interleukin-1Ra significantly reduced levels of IL-6 and C-reactive protein (p < 0.001). Fibrinogen levels were also reduced in the active arm of the study (p < 0.002). Subcutaneous IL-1Ra was safe, well tolerated, and had a predictable plasma pharmacokinetic profile. Although the study was not powered to investigate clinical effect, scores of the Glasgow Outcome Scale–extended at 6 months were better in the active group; however, this outcome did not reach statistical significance.
Subcutaneous IL-1Ra is safe and well tolerated in aSAH. It is effective in reducing peripheral inflammation. These data support a Phase III study investigating the effect of IL-1Ra on outcome following aSAH.
AdamczykPHeSAmarAPMackWJ: Medical management of cerebral vasospasm following aneurysmal subarachnoid hemorrhage: a review of current and emerging therapeutic interventions. Neurol Res Int2013:4624912013
BlamireAMAnthonyDCRajagopalanBSibsonNRPerryVHStylesP: Interleukin-1β-induced changes in blood-brain barrier permeability, apparent diffusion coefficient, and cerebral blood volume in the rat brain: a magnetic resonance study. J Neurosci20:8153–81592000
GaleaJOgungbenroKHulmeSGreenhalghAAaronsLScarthS: Intravenous anakinra can achieve experimentally effective concentrations in the central nervous system within a therapeutic time window: results of a dose-ranging study. J Cereb Blood Flow Metab31:439–4472011
GilliamBEReedMRChauhanAKDehlendorfABMooreTL: Evidence of fibrinogen as a target of citrullination in IgM rheumatoid factor-positive polyarticular juvenile idiopathic arthritis. Pediatr Rheumatol Online J9:82011
GreenhalghADBroughDRobinsonEMGirardSRothwellNJAllanSM: Interleukin-1 receptor antagonist is beneficial after subarachnoid haemorrhage in rat by blocking haem-driven inflammatory pathology. Dis Model Mech5:823–8332012
GueorguievaIClarkSRMcMahonCJScarthSRothwellNJTyrrellPJ: Pharmacokinetic modelling of interleukin-1 receptor antagonist in plasma and cerebrospinal fluid of patients following subarachnoid haemorrhage. Br J Clin Pharmacol65:317–3252008. (Erratum in BR J Clin Pharmacol 66: 754 2008)
GueorguievaIOgungbenroKGrahamGGlattSAaronsL: A program for individual and population optimal design for univariate and multivariate response pharmacokinetic-pharmacodynamic models. Comput Methods Programs Biomed86:51–612007
HelmyAGuilfoyleMRCarpenterKLHPickardJDMenonDKHutchinsonPJ: Recombinant human interleukin-1 receptor antagonist in severe traumatic brain injury: a phase II randomized control trial. J Cereb Blood Flow Metab34:845–8512014
Jedrzejowska-SzypułkaHLarysz-BryszMKuklaMSnieturaMLewin-KowalikJ: Neutralization of interleukin-1β reduces vasospasm and alters cerebral blood vessel density following experimental subarachnoid hemorrhage in rats. Curr Neurovasc Res6:95–1032009
McCollBWRothwellNJAllanSM: Systemic inflammatory stimulus potentiates the acute phase and CXC chemokine responses to experimental stroke and exacerbates brain damage via interleukin-1- and neutrophil-dependent mechanisms. J Neurosci27:4403–44122007
MichaelBDGriffithsMJGranerodJBrownDKeirGWnękG: The interleukin-1 balance during encephalitis is associated with clinical severity, blood-brain barrier permeability, neuroimaging changes, and disease outcome. J Infect Dis213:1651–16602016
SchiffMHDiVittorioGTesserJFleischmannRSchechtmanJHartmanS: The safety of anakinra in high-risk patients with active rheumatoid arthritis: six-month observations of patients with comorbid conditions. Arthritis Rheum50:1752–17602004
SinghNHopkinsSJHulmeSGaleaJPHoadleyMVailA: The effect of intravenous interleukin-1 receptor antagonist on inflammatory mediators in cerebrospinal fluid after subarachnoid haemorrhage: a phase II randomised controlled trial. J Neuroinflammation11:12014
TeasdaleGMDrakeCGHuntWKassellNSanoKPertuisetB: A universal subarachnoid hemorrhage scale: report of a committee of the World Federation of Neurosurgical Societies. J Neurol Neurosurg Psychiatry51:14571988
TurnerCLBudohoskiKSmithCHutchinsonPJKirkpatrickPJMurrayGD: Elevated baseline C-reactive protein as a predictor of outcome after aneurysmal subarachnoid hemorrhage: data from the Simvastatin in Aneurysmal Subarachnoid Hemorrhage (STASH) trial. Neurosurgery77:786–7932015